Friday February 24th 2017: Johnson & Johnson, JNJ is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in USA, Johnson & Johnson, JNJ has a market cap of 363.63 B. Since its IPO date on the 01/02/1970, Johnson & Johnson, JNJ performance year to date is 16.61%. Today Johnson & Johnson, JNJ has gained 0.98%, with a current price of 134.35.
Ownership of the company is 0.02% for insider ownership while institutional ownership is 67.90%. The management of the company have seen the company have a payout ratio of 52.80%. Return of assets are at 11.70%, with return on investment at 17.00%.
In terms of debt levels and profit levels, Johnson & Johnson, JNJ is seeing a long-term debt/equity of 0.38. While Total debt/equity is 0.46. With a profit margin of 22.90%, this is combined with a gross margin of 69.90%, and operating margin of 27.80%. Johnson & Johnson ability to meet debt levels, with a current ratio of 2.5, while the quick ratio is 2.2.
For the last year Johnson & Johnson, JNJ has seen a EPS growth of 8.30%. A performance for the year of 15.18%. The 52-week high is 0.59%, and the 52-week low is 22.90%. The average volume for Johnson & Johnson, JNJ is 12639630.
With a target price of 130.72, can Johnson & Johnson, JNJ reach this target? Looking at the value indicators of Johnson & Johnson, JNJ. Johnson & Johnson has a P/E of 22.58 and a forward P/E of 17.51. Perhaps the more useful indicator than P/E, is PEG which has a value of 3.5. Johnson & Johnson also has a P/S and a P/B of 5.04 and 5.17 respectively. For P/cash, Johnson & Johnson has a value of 9.24, while it is 42.45 for P/free cash flow.
At the current price of 134.35, Johnson & Johnson has a dividend yield of 2.50%. We see a return on equity of 23.10%.
Looking more long-term Johnson & Johnson, is projected to get an EPS growth for the next five years of 6.45%. In the short-term an EPS growth of 7.99% in the next year is forecasted. This is after a EPS growth of 8.30% for this year and for the last five years a 11.20% growth has been seen.